Arpraziquantel for schistosomiasis in young children
Part of Infections clinical trials.
This study tests a new medicine called arpraziquantel to treat schistosomiasis (a disease from parasites in water) in young children aged 2 to 5. It aims to see if giving this treatment in communities where the disease is common is safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lived in the study area for at least 6 months.
- Your child is between 2 and 5 years old (24 to 59 months).
- You or your child’s guardian give permission (informed consent).
- Your child does not have a serious illness or trouble taking medicine by mouth.
- Your child has never had a seizure.
- Your child is not allergic to praziquantel.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving treatment for schistosomiasis (a parasite infection) more often helps reduce liver scarring (fibrosis). It compares different schedules of medication to see which works best and may improve liver health.
This study tests whether giving preventive medicine to people who move or migrate can help control river blindness and lymphatic filariasis. It focuses on children and household heads who have missed past treatment rounds.
This trial looks at how active a long-term schistosomiasis infection is in travelers and migrants. It aims to better understand the infection to help guide treatment.
This study tests if higher doses of arpraziquantel can safely treat children infected with the liver fluke Opisthorchis viverrini. It aims to find the best dose that clears the infection.
This study tests if giving schoolchildren malaria-prevention medicine at certain times can lower malaria in the community. It might help protect your child and others from getting sick.
This trial tests a medicine called tafenoquine, which is used to treat malaria. It aims to see how well it works in children with uncomplicated malaria, and participants will also receive standard malaria treatments.
Hear when a new Schistosomiasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.